Background: A potential protective role for estrogen in colon carcinogenesis has been suggested
Introduction
Exogenous hormones are linked to CRC risk reduction (1, 2) , yet risks associated with circulating estrogens are elevated (3, 4) , or null (5) . In normal colonic tissue, ERα enhances cell growth and is expressed at low levels, while the anti-proliferative ERβ is abundant (6) . In neoplastic colonic tissue this is reversed. Estradiol binds to both receptors with comparably high affinity, but at least one estrogen metabolite (EM), 17-epiestriol, shows a binding preference for ERβ (7) . We speculated that selective binding of EM to ERα or ERβ may influence colon carcinogenesis.
Thus, we investigated the association between a panel of EM and CRC in B~FIT.
Materials and Methods
FIT, a randomized trial designed to test alendronate, screened 22,695 postmenopausal women aged 55 to 80 from 1992 to 1993, who provided a bone mineral density scan (BMD), blood and information on demographic, lifestyle and reproductive factors through a self-administered questionnaire. B~FIT comprises 15,595 of the FIT screenees followed for incident cancer through December 2004. An additional questionnaire covering subsequent cancer diagnoses was sent to these participants (8).
Self-reported cancers were confirmed by medical records and/or cancer registries. Additional cases were identified from cancer registries. Vital status was determined by the National Death Index. All participants provided written informed consent and Institutional Review Board approval was obtained from all clinical sites and the National Cancer Institute.
This analysis was part of a case-cohort study within B~FIT examining EM in relation to CRC, breast, endometrial and ovarian cancer (8) . We studied 187 CRC cases (10 in the subcohort) and EM were examined individually, by pathway (C-2, C-4 or C-16 hydroxylation, with EM in each pathway summed), and by ratios of pathways. Cox proportional hazards regression models with robust variance adjustment were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). For cases not in the subcohort, follow-up began 6 months prior to CRC diagnosis and ended at diagnosis. For the subcohort, follow-up began at baseline and ended at CRC diagnosis for cases (n=10), and death or end of follow-up for non-cases (n=491). Covariates examined included BMI, parity, smoking, postmenopausal hormone use, and ages at menarche, birth of first child and menopause. The final model adjusted for clinic site, trial participation status, age at blood collection and total BMD. No adjustment was made for multiple comparisons.
Results
Descriptive characteristics and HR for lifestyle/reproductive risk factors are presented (Table 1 ).
Compared to the subcohort, cases were older at study entry, followed for fewer years, and had lower BMD at baseline. Current smokers experienced a 40% increased risk, and women with a late age at menopause had >2-fold excess risk, but HR for other factors were not statistically significant.
Women with higher total EM were not at elevated risk compared to those in the lowest quartile 
Discussion
This first prospective study of EM and CRC risk found no evidence for associations with these hormones. There was a suggestion of a slight effect for 17-epiestriol, but this may have occurred by chance given the number of comparisons. Our lack of association is consistent with results from one study (5) but not others (3, 4) showing modest elevated risks for estradiol or estrone.
Reasons for these disparate findings are not clear. Women in our study were older (mean age 67 vs 60 to 64 in prior studies), but all involved postmenopausal women not using menopausal hormones at blood draw. The studies were of comparable size; however, unlike others, BMI was not associated with CRC in our study. Additionally, immunoassays for estrogens in prior studies may not detect the low levels in postmenopausal women.
Estrogen is not central to the etiology of CRC, but the change from predominantly ERβ expression in the healthy colon to ERα in neoplastic tissue suggests it may afford protection in the healthy colon, but promote tumorigenesis once neoplastic changes occur. However, results from observational studies of endogenous and exogenous estrogens are not consistent (1, 2).
In summary, while our apparent lack of association between endogenous estrogens is at odds with findings of reduced risk associated with exogenous hormone use, additional well-powered 
studies are needed to improve our understanding of the exogenous hormone and CRC association.
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